Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Decitabine in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT04510610Phase 3Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, decitabine in Classical Hodgkin Lymphoma (cHL), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
camrelizumabdecitabine
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT04510610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510610.